Canagliflozin is an oral drug which is currently approved for use in patients with type 2
diabetes by the US Food and Drug Administration (FDA). Canagliflozin acts by increasing salt
and sugar loss in the urine, and has shown to protect heart, kidney, and blood vessel
function in patients with type 2 diabetes. However, it is unknown how canagliflozin protects
the kidneys from disease. Therefore, this study plans to learn more about how canagliflozin
works to protect against diabetic kidney disease in adults with type 2 diabetes. This study
will use state-of-the-art kidney imaging, kidney biopsies and detailed testing of kidney
function to determine the mechanisms of protection afforded by canagliflozin.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Boston Medical Center Brigham and Women's Hospital University of Michigan